Top Industry News

Regeneron Pharmaceuticals, a Tarrytown, New York-based bio/pharmaceutical company, and Telix Pharmaceuticals, a Melbourne, Australia-based clinical-stage bio/pharmaceutical company, have entered a collaboration to jointly develop and commercialize radiopharmaceutical therapies, in a deal worth up to $2.1 billion ($40…

In a move to focus on its core prescription drug business, Daiichi Sankyo has agreed to divest its consumer healthcare business, Daiichi Sankyo Healthcare Co. (DSHC), to Suntry Holdings, an Osaka Japan-based food and…

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for treating RAS-addicted cancers, is seeking to raise $2 billion through a follow-on stock offering of 10.56 million shares priced at $142…

The latest from CDMOs, CMOs, and suppliers featuring Kincell Bio, Fujifilm Biotechnologies, Evotec, Symbiosis, Bora Biologics and Ardena.   Appointments * Dow Names New CEO* Evotec Appoints New Chief Operating OfficerBiologics Manufacturing * Kincell Bio Expanding Cell-Therapy Mfg Facility * Fujifilm…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring GSK and Eli Lilly and Company. Highlights below.   For the latest news roundup on small and Emerging Pharma companies,…

The latest from small and Emerging Pharma companies featuring Aligos Therapeutics, Xiamen Amoytop Biotech, Spyre Therapeutics, Beeline Medicines, Allogene Therapeutics, and Terremoto Biosciences.  For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs.  * Aligos Therapeutics,…

Gilead Sciences has agreed to acquire Tubulis, a Munich, Germany-based clinical-stage bio/pharmaceutical company developing antibody-drug conjugates (ADCs), in a deal worth up to $5 billion ($3.15 billion upfront and $1.85 billion in milestone payments).  The acquisition will expand Gilead’s ADC capabilities by adding…

Neurocrine Biosciences, a San Diego, California-based bio/pharmaceutical company, has agreed to acquire Soleno Therapeutics, a Redwood City, California-based bio/pharmaceutical company, for $2.9 billion.  The acquisition will add Vykat XR (diazoxide choline), a therapy to treat hyperphagia (extreme, insatiable…

The US Environmental Protection Agency (EPA) Administrator Lee Zeldin and US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. announced last week (April 2, 20269 coordinated…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Shionogi and Gilead Sciences. Highlights below.   For the latest news roundup on small and Emerging Pharma companies, see Biotech…